Literature DB >> 8313578

Relation of clinical presentation, stenosis morphology, and operator technique to the procedural results of rotational atherectomy and rotational atherectomy-facilitated angioplasty.

S G Ellis1, J J Popma, M Buchbinder, I Franco, M B Leon, K M Kent, A D Pichard, L F Satler, E J Topol, P L Whitlow.   

Abstract

BACKGROUND: Rotational atherectomy using the Rotablator has recently become available to treat coronary stenoses. This study was performed to determine the relation of patient characteristics, stenosis morphology, and operator technique to procedural outcome to gain insight into which patients might be best treated with this device. METHODS AND
RESULTS: Four hundred stenoses from 316 patients randomly selected from the initial Rotablator experience at three major referral institutions were analyzed. Angiographic data were assessed at a central angiographic laboratory using standardized morphological criteria and caliper measurement. Patients were somewhat more elderly than most percutaneous transluminal coronary angioplasty (PTCA)-treated groups (mean age, 64 +/- 11 years), 74% were men, and the lesions treated were often complex (modified American College of Cardiology/American Heart Association lesion type A, 24%; B1, 40%; B2, 30%; and C, 6%). Elective adjunctive PTCA was used for 82% of stenoses treated. Procedural success was achieved in 89.8% of stenoses (93.5% if results with creatine kinase two to three times normal are not counted as failures), and major ischemic complications (death, 0.3%; non-Q-wave myocardial infarction, 5.7%; Q-wave myocardial infarction, 2.2%; or emergency bypass surgery, 0.9%) occurred in 8.9% of patients. Complications were due to epicardial coronary obstruction in 3.8% of patients and to delayed coronary runoff ("slow reflow") in 5.1% of patients. Procedural failure was correlated independently with outflow obstruction (success rate, 64%; odds ratio for failure, 5.4; multivariate P = .002), lesion irregularity (76%; odds ratio, 3.3; P = .003), stenosis bend > or = 60 degrees (73%; odds ratio, 3.7; P = .03), and female sex (84%; odds ratio, 2.4; P = .03). Ischemic complications were correlated independently with lesion length (> or = 50% narrowing) > or = 4 mm (complication rate, 12%; odds ratio, 3.6; multivariate P = .005), right coronary artery stenosis (13%; odds ratio, 2.4; P = .02), stenosis bend > or = 60 degrees (27%; odds ratio, 6.1; P = .03), and female sex (13%; odds ratio, 3.0; P = .04). Slow reflow was correlated with total burring duration (odds ratio, 1.005/s; multivariate P = .001), right coronary artery stenosis (incidence, 17%; odds ratio, 4.5; P = .009), and to a lesser extent with recent myocardial infarction in the treated territory (44%; odds ratio, 4.3; P = .08).
CONCLUSIONS: The procedural outcome of rotational atherectomy is highly correlated with stenosis morphology and location and sex of the patient. After stratification for these parameters, overall outcome with the Rotablator appears to be similar to that with balloon angioplasty and other competing techniques. Short-term outcome with specific subsets of patients may be superior with the Rotablator (calcified stenoses), but this technique might best be avoided in some patients (those with irregular or possibly thrombus-containing stenoses, highly angulated stenoses, and possible right coronary artery stenoses or those associated with impaired distal runoff caused by a recent myocardial infarction or manifest by a fixed thallium defect).

Entities:  

Mesh:

Year:  1994        PMID: 8313578     DOI: 10.1161/01.cir.89.2.882

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  14 in total

1.  Mechanisms of myocardial hypoperfusion during rotational atherectomy of de novo coronary artery lesions and stenosed coronary stents: insights from serial myocardial scintigraphy.

Authors:  Karl-Christian Koch; Peter W Radke; Eduard Kleinhans; Susanne Ninnemann; Uwe Janssens; Heinrich G Klues; Udalrich Buell; Peter Hanrath; Juergen vom Dahl
Journal:  J Nucl Cardiol       Date:  2002 May-Jun       Impact factor: 5.952

Review 2.  [Rotational atherectomy: technique, indications, results].

Authors:  T Dill; C W Hamm
Journal:  Herz       Date:  1997-12       Impact factor: 1.443

3.  Is rotational atherectomy here to stay?

Authors:  P L Whitlow
Journal:  Heart       Date:  1997-10       Impact factor: 5.994

4.  Usability of cardiac magnetic resonance imaging for procedural myocardial infarction undergoing rotational atherectomy.

Authors:  Hidetoshi Chibana; Fumiaki Ikeno
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

5.  Impact of platelet glycoprotein IIb/IIIa inhibitor therapy on in-hospital outcomes and long-term survival following percutaneous coronary rotational atherectomy.

Authors:  Jeffrey S Berger; James N Slater; Warren Sherman; Stephen J Green; Timothy A Sanborn; David L Brown
Journal:  J Thromb Thrombolysis       Date:  2005-02       Impact factor: 2.300

Review 6.  Coronary microembolization--its role in acute coronary syndromes and interventions.

Authors:  R Erbel; G Heusch
Journal:  Herz       Date:  1999-11       Impact factor: 1.443

Review 7.  Interventional Options for Coronary Artery Calcification.

Authors:  Matthew I Tomey; Samin K Sharma
Journal:  Curr Cardiol Rep       Date:  2016-02       Impact factor: 2.931

Review 8.  Restenosis following coronary angioplasty: current status.

Authors:  M K Hong
Journal:  Korean J Intern Med       Date:  2001-06       Impact factor: 2.884

9.  Clinical Outcomes of Patients Undergoing Rotational Atherectomy Followed by Drug-eluting Stent Implantation: A Single-center Real-world Experience.

Authors:  Lucky R Cuenza; Ada Cherryl Jayme; James Ho Khe Sui
Journal:  Heart Views       Date:  2017 Oct-Dec

10.  Pharmacological prevention of peri-, and post-procedural myocardial injury in percutaneous coronary intervention.

Authors:  Hideki Ishii; Tetsuya Amano; Tatsuaki Matsubara; Toyoaki Murohara
Journal:  Curr Cardiol Rev       Date:  2008-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.